Genome & Company

Genome & Company is a clinical-stage biotechnology company that researches and develops novel-targeted immuno-oncology therapeutics, with activities in immuno-oncology, skin diseases, and autism. It operates in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate designed to have immune-modulating activity. The company also develops GEN-501, which targets non-responders to Dupilumab drugs in atopic skin diseases, and GENA-104 for the treatment of solid tumors, along with microbiome-based products including therapeutics, cosmeceuticals, and dietary supplements. It has a partnership with US-based Scioto Biosciences for the development of SB-121, which targets gut-brain axis disorders such as Autism Spectrum Disorder (ASD) and gut-injury-related disorders including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.